This inventor holds 1 USPTO granted patent and 2 published patent applications and 3 EPO patents. Top assignee: Meiragtx Gene Regulation Limited. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Kathleen Börner - Innovator in Gene Therapy
Introduction
Kathleen Börner is an accomplished inventor based in Schriesheim, Germany. She has made significant contributions to the field of gene therapy, particularly in the development of innovative treatments for arthritic diseases. Although she currently holds no granted patents, her work continues to influence the scientific community.
Latest Patent Applications
Kathleen Börner's latest patent applications include:
1. **Modified AAV Capsid Proteins for Treatment of Arthritic Disease** - This invention relates to recombinant adeno-associated virus (rAAV) virions for gene therapy. The rAAV virions comprise a novel capsid protein, which is utilized in gene therapy for treating arthritic diseases, such as rheumatoid arthritis, preferably through intraarticular administration.
2. **Modified rAAV Capsid Protein for Gene Therapy** - Similar to her previous application, this invention also focuses on recombinant adeno-associated virus (rAAV) virions for gene therapy. It emphasizes the use of novel capsid proteins in treating arthritic diseases, particularly rheumatoid arthritis, through intraarticular administration.
Conclusion
Kathleen Börner's innovative work in gene therapy showcases her dedication to advancing medical treatments for arthritic diseases. Her contributions, although not yet reflected in granted patents, highlight her potential impact in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile